𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibitors of GABA metabolism: Implications for Huntington's disease

✍ Scribed by Robert Schwarcz; James P. Bennett Jr; Dr. Joseph T. Coyle

Publisher
John Wiley and Sons
Year
1977
Tongue
English
Weight
467 KB
Volume
2
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Stereotaxic injection of kainic acid into rat striatum produces neuronal degeneration and neurochemical alterations resembling Huntington's disease (HD). Since correction of the deficiency in γ‐aminobutyric acid (GABA) in HD may be of therapeutic value, the efficacy of drugs that inhibit the GABA‐degrading enzyme (GABA‐T) in elevating the levels of GABA has been examined in the animal model for HD. High doses of di‐N‐propylacetic acid only partially correct the GABA deficiency in the striatum, whereas low doses of γ‐acetylenic GABA, a specific irreversible inhibitor of GABA‐T, completely restore the levels of GABA in striatum and substantia nigra.

📜 SIMILAR VOLUMES

A novel target for Huntington's disease:
A novel target for Huntington's disease: ERK at the crossroads of signaling : The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology
✍ Bodai, László (author);Marsh, J. Lawrence (author) 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 300 KB 👁 1 views

## Abstract Activating the ERK pathway (extracellular signal‐regulated kinase pathway) has proven beneficial in several models of Huntington's disease (HD), and drugs that are protective in HD models have recently been found to activate ERK. Thus, the ERK cascade may be a potential target for thera